Phase 3 N=60 Randomized Quadruple-blind Treatment

Efficacy of TAP Block in Cesarean Section Patients

Pain Control

Bottom Line

View on ClinicalTrials.gov: NCT03493828 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Nov 2018

Primary outcome: Primary: Effect of Transversus Abdominis Plane (TAP) Block Using Either 0.5% or 0.25% Bupivacaine on Analgesia for Cesarean Section Patients When Compared to Placebo. — 9.45; 8.95; 17.65 PCA bolus

Study Design & Population

Study type: Interventional
Phase: Phase 3
Interventions: TAP block using Bupivacaine 0.5% (Procedure); TAP block using Bupivacaine 0.25% (Procedure); TAP block using Normal Saline (Procedure)
Age: Pediatric, Adult, Older Adult
Sex: Female
Sponsor: New York Presbyterian Brooklyn Methodist Hospital
Primary completion: Oct 2013

Outcome Measures

Outcome	Result	p-value
PRIMARY Effect of Transversus Abdominis Plane (TAP) Block Using Either 0.5% or 0.25% Bupivacaine on Analgesia for Cesarean Section Patients When Compared to Placebo.	9.45; 8.95; 17.65	—

Summary

TAP Block done with 2 different concentrations of bupivacaine and placebo

Eligibility Criteria

Inclusion Criteria

Healthy pregnant women

Exclusion Criteria

Allergy to local anesthetics

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03493828). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.